Key result
MicroRNAs regulate doxorubicin-induced DNA damage responses, presenting potential therapeutic targets for cardiotoxicity.
Why the study?
Doxorubicin use is limited by cardiotoxicity, and understanding how miRNAs regulate downstream DNA damage response pathways is necessary for developing future cardioprotective therapies.
This review highlights the role of microRNAs in mediating doxorubicin-induced cardiotoxicity through DNA damage response pathways, offering potential targets for future cardioprotective therapies.
Answers are grounded in this paper and cite their sources.
MicroRNA targeting should not yet change doxorubicin cardiotoxicity management; leaves open validation of specific pathways in prospective trials.
Doxorubicin (DOX) is a chemotherapeutic drug widely used for cancer treatment, but its use is limited by cardiotoxicity. Although free radicals from redox cycling and free cellular iron have been predominant as the suggested primary pathogenic mechanism, novel evidence has pointed to topoisomerase II inhibition and resultant genotoxic stress as the more fundamental mechanism. Recently, a growing list of microRNAs (miRNAs) has been implicated in DOX-induced cardiotoxicity (DIC). This review summarizes miRNAs reported in the recent literature in the context of DIC. A particular focus is given to miRNAs that regulate cellular responses downstream to DOX-induced DNA damage, especially p53 activation, pro-survival signaling pathway inhibition (e.g., AMPK, AKT, GATA-4, and sirtuin pathways), mitochondrial dysfunction, and ferroptosis. Since these pathways are potential targets for cardioprotection against DOX, an understanding of how miRNAs participate is necessary for developing future therapies.
No takes yet. Share an insight, caveat, or question.
Kawano et al. (2022) conducted a review in Doxorubicin-induced cardiotoxicity. Doxorubicin was evaluated. MicroRNAs regulate cellular responses downstream to doxorubicin-induced DNA damage, including p53 activation and mitochondrial dysfunction, presenting potential therapeutic targets for cardiotoxicity.
Synapse has enriched 10 related papers. Consider them for comparative context: